novo nordisk glp 1 oral strikes $2.1bn obesity biologic deal with Vivtex | News GLP-1 battle heats up again

While we included extensive data on comorbidities and concomitant medications, information on reasons for treatment discontinuation, such as gastrointestinal adverse effects, was not available

In terms of cost-effectiveness, traditional therapies are generally inexpensive but may incur higher long-term costs due to treatment failures, drug resistance, and management of adverse effects

will remain the leading driver of obesity drug revenue, emerging and middle-income markets represent crucial avenues for global expansion and public health impact

People turn to the grey market because the legitimate healthcare system has failed them in one or more ways, and understanding those failures matters for evaluating the full picture

Some foods trigger hot flashes, Hulon said

Effortless Daily Use: One patch provides up to 8 hours of steady nutrient delivery with no mixing, measuring, or cleanup